Authors


James E. Galvin, MD, MPH

Latest:

Expanding the Pathways to Treat Dementia With Lewy Bodies: James Galvin, MD, MPH

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine detailed the need for improved biomarkers of dementia with Lewy bodies and whether research in Alzheimer disease helps propel the field. [WATCH TIME: 3 minutes]


John F. Crary, MD, PhD

Latest:

The Future of Digital Neuropathology and the Role of AI: John F. Crary, MD, PhD; Gerardo Fernandez, MD

The neuropathologist at Mount Sinai and chief science officer of Precise Dx pairing spoke to the role of artificial intelligence in the diagnosis of diseases from peripheral tissue biopsies and its ability to improve neuropathology. [WATCH TIME: 8 minutes]


John Greenfield, MD, PhD

Latest:

AI in Academic Neurology: A Chat With ChatGPT-4

L. John Greenfield Jr, MD, PhD, “spoke” about the future of artificial intelligence in neurology with ChatGPT-4—one of the largest language modules that have grabbed the field’s interest.


Cathleen Lutz, PhD

Latest:

Steps to Validate Stathmin-2 as an ALS-Specific Biomarker: Cathleen Lutz, PhD

The vice president of the Rare Disease Translational Center at the Jackson Laboratory provided commentary on the next steps needed to further understand stathmin-2’s role as a potential disease-modifying biomarker. [WATCH TIME: 3 minutes]


Lauren Gluck, MD

Latest:

Challenges of Shared Decision-Making in the Management of Multiple Sclerosis

Although challenging, shared decision-making is a rewarding part of the practice of medicine. Involving patients in therapeutic decisions can improve patient autonomy and satisfaction—but it is not easy to implement.


Anita Shelgikar, MD, MHPE

Latest:

The Importance of Sleep Medicine Education: Anita Shelgikar, MD, MHPE

The clinical associate professor of neurology at the University of Michigan spoke on the importance of sleep medicine education for trainees, as well as areas that could be improved. [WATCH TIME: 3 minutes]


This is where the author name appears

Latest:

SPONSORED ARTICLE TEMPLATE

This is the deck of the article. It can be used to provide further context to the headline and provides search engines with summary text for social posts.


Deena Kuruvilla, MD

Latest:

The Mini-Prevention Concept in Migraine Care: Deena Kuruvilla, MD

The medical director of the Westport Headache Institute spoke to the role that devices can play in layered and variable treatment approaches, and how this better lends itself to offering personalized treatment to different individuals with migraine


Thomas F. Scott, MD

Latest:

New Insights into BTK Inhibitors and MRI Techniques for Smoldering MS: Thomas F. Scott, MD

The director of the Allegheny Multiple Sclerosis Treatment Center at Allegheny General Hospital discussed exploring the potential role of BTK inhibitors and advanced MRI techniques to address smoldering multiple sclerosis. [WATCH TIME: 10 minutes]


Emily Harrington, MD, PhD

Latest:

Tackling Neurodegeneration in Multiple Sclerosis: Emily Harrington, MD, PhD

The assistant professor of neurology at The Ohio State University Wexner Medical Center provided insight on finding strategies to prevent neurodegeneration in multiple sclerosis. [WATCH TIME: 3 minutes]


Lawrence Steinman, MD

Latest:

Evolution of Anti-CD20 Disease Modifying Therapies in Multiple Sclerosis - Recent Updates

In this episode of MEDcast, expert neurologists delve into anti-CD20 disease modifying therapies (DMTs) in MS. They assess the correlation between clinical observations and immunological processes in MS patients, and also examine the role of the Epstein Barr virus in MS.


Teri Schreiner, MD

Latest:

Balancing COVID-19 Infection Risk and Disease Control in Pediatric Onset MS: Teri Schreiner, MD

The associate professor at the University of Colorado highlighted the limitations of standard care visits in collecting crucial data from pediatric multiple sclerosis centers. [WATCH TIME: 3 minutes]


Caroline Just, MD, FRCPC, CSC-EEG

Latest:

Rare Diseases Are More Common Than Their Name May Imply

Caroline Just, MD, reflects on the challenges of diagnosing and treating rare neurological diseases, urging for improved education, collaboration, and research efforts.


Adel M. Malek, MD, PhD

Latest:

A New Approach to Communicating Hydrocephalus: An Overdue Opportunity

A pair of cerebrovascular and neurosurgery experts discuss a novel approach to communicating hydrocephalus with an arachnoid granulation using a miniature implant, delivered via a percutaneous endovascular catheter.


Ruth Ann Marrie, MD, PhD, FRCPC

Latest:

Future Implications of New Framework to Characterize Multiple Sclerosis: Ruth Ann Marrie, MD, PhD, FRCPC

The professor of medicine at the University of Manitoba detailed the implications of a new paper suggesting changes to the characterization of MS phenotypes and how it might impact previously approved therapies. [WATCH TIME: 3 minutes]


Michael Hotchkin

Latest:

Unique Composition of CNM-Au8 to Treat MS and ALS: Michael Hotchkin

The chief development officer at Clene Nanomedicine provided insight on why CNM-Au8, an investigational agent in development, has shown positive results across both multiple sclerosis and ALS. [WATCH TIME: 2 minutes]


Benjamin Claytor, MD

Latest:

Understanding the Utility of Specific Antibody Testing in Peripheral Neuropathies: Benjamin Claytor, MD

The assistant professor of neurology at Cleveland Clinic provided insight on the differences in ganglioside vs paranodal antibodies and their clinical use in various neuropathies. [WATCH TIME: 3 minutes]


Jemima Akinsanya, DO

Latest:

Understanding Mechanisms of MS Chronic Inflammation: Jemima Akinsanya, DO, and Daniel Reich, MD, PhD

The duo from the National Institutes of Health discussed how monitoring and treating paramagnetic rim lesions can improve patient care in multiple sclerosis.


Carlos A. Pardo-Villamizar, MD

Latest:

Patient-Centric Theme of SRNA’s 2022 Rare Neuroimmune Disorders Symposium: Carlos A. Pardo-Villamizar, MD

The professor of neurology at Johns Hopkins Medicine provided an in-depth look at the 2022 RNDS and the unique design it offers patients with rare neuroimmune disorders. [WATCH TIME: 3 minutes]


Jai Perumal, MD

Latest:

Benefits of Telemedicine and Access to Treatments for Multiple Sclerosis: Jai Perumal, MD

The associate professor of clinical neurology at Weill Cornell Medicine discussed the progress made in multiple sclerosis in terms of expanding access to therapies and the challenges that persist for progressive forms of the disease in the field. [WATCH TIME: 10 minutes]


Nicholas E. Johnson, MD, MSci

Latest:

Successes and Challenges in the New Era of Genetic Medicine: Nicholas E. Johnson, MD, MSci

The division chief of neuromuscular disorders and vice-chair of research at Virginia Commonwealth University spoke to the ongoing success in the development of gene-mediated therapies and the challenges that come along with treating rare neuromuscular disease. [WATCH TIME: 3 minutes]


Mustafa Saad Siddiqui, MD

Latest:

COVID-19 Shutdowns and the Disruption to Deep Brain Stimulation Treatment

While shutdowns disrupted care for all patients with Parkinson disease, hospitals were forced to postpone elective procedures such as the initial DBS device implantation and implantable pulse generator replacements.


Michael Kaplitt, MD, PhD

Latest:

The Promising Future of Gene Therapy in Treating Neurological Diseases: Michael Kaplitt, MD, PhD

The professor of neurological surgery at Weill Cornell medicine talked about how gene therapy may offer a more direct and efficient pathway to develop treatments for neurological diseases like Parkinson disease. [WATCH TIME: 6 minutes]


Amanda Hare, DNP

Latest:

Improving Access to Care in Parkinson Disease: Expanding Objective Diagnostics and Telemedicine

Standardizing protocols and incorporating objective diagnostics and telemedicine can enhance care for patients with PD and alleviate the burden on healthcare systems.


Louis Ferrari, RPh, MBA

Latest:

Balancing New Medications and Reducing Adverse Effects in Epilepsy Treatment: Louis Ferrari, RPh, MBA

The vice president of medical affairs at SK Life Science talked about findings from a new post-hoc analysis which highlighted the importance of strategically reducing concomitant medications to minimize adverse events of epilepsy treatment. [WATCH TIME: 5 minutes]


Lori Lonczak, MBA, RPh

Latest:

Digital Health Tool Offers Innovative Quantitative Fall Assessment Solution for Older Adults

Falls cost the US more than $50 billion annually, but platforms like CatchU, a transformative digital health tool, provide quantitative fall assessment that might significantly enhance the current standard of care for predicting falls.


Marian LaMonte, MD, MSN, FAAN

Latest:

Improving Stroke Discharge Outcomes: Marian LaMonte, MD, MSN, FAAN

The chief of neurology at Ascension Saint Agnes discussed the interventions her team implemented to improve patient-specific stroke discharge instructions.


Jessica Yi, MD

Latest:

A Practical Approach to Chronic Immunosuppression in Myasthenia Gravis

A practical approach to initiating and tapering corticosteroids, and the considerations in the selection and monitoring parameters of steroid-sparing agents are crucial to the care of myasthenia gravis.


Laurits Taul Madsen, PhD-C

Latest:

Using Neuromuscular Function as a Risk Factor for Falls in Multiple Sclerosis: Laurits Taul Madsen, PhD-C

The PhD student at Aarhus University provided insight on his study presented at 2022 ECTRIMS Congress on an innovative way using neuromuscular measures to discriminate those with MS at high risk for falls. [WATCH TIME: 2 minutes]


Josh Cohen, BSc

Latest:

Reactions to FDA Advisory Panel Decision on AMX0035: Justin Klee; Josh Cohen, BSc

The co-CEOs and co-founders of Amylyx Pharmaceuticals discussed their immediate thoughts to the recent FDA AdComm meeting, which voted against evidence of efficacy for AMX0035 in ALS. [WATCH TIME: 3 minutes]

© 2024 MJH Life Sciences

All rights reserved.